Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00070941 · ClinicalTrials.gov registry record · Phase 2

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

A Phase 2 study of Depression and Parkinson's Disease, sponsored by NYU Langone Health.

Completed
Registry status
Phase 2
Development phase
29
Enrollment target
1
Study location

NCT00070941 is a Phase 2 study of Depression and Parkinson's Disease that has completed, run by NYU Langone Health. The registered enrollment target is 29 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00070941, a Phase 2 study of Depression and Parkinson's Disease, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
Phase 2
Development phase
29 participants
Enrollment target
1
Study location

Study Summary

This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).

Conditions Studied

Depression Parkinson's Disease

Interventions

  • DRUG placebo
  • DRUG SAM-e
  • DRUG oral escitalopram

Study Locations (1)

New York

  • New York University - New York

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2003-07
Est. Completion 2010-10
Phase Phase 2

Sponsor

NYU Langone Health

1,164 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00070941

The ClinicalTrials.gov registry entry for NCT00070941 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00070941 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00070941 about?

NCT00070941 is a clinical study titled "SAM-e for the Treatment of Depression in Patients With Parkinson's Disease". This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).

What is the current status of trial NCT00070941?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2003-07. Estimated completion is 2010-10.

What conditions does trial NCT00070941 study?

This clinical trial studies the following conditions: Depression, Parkinson's Disease.

What interventions are being tested in trial NCT00070941?

The interventions under investigation include: placebo (DRUG), SAM-e (DRUG), oral escitalopram (DRUG).

Who is sponsoring clinical trial NCT00070941?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00070941 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depression

All registered trials for this condition

Parkinson's Disease

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.